Anti-CCR8 antibodies
The present disclosure provides anti-CCR8 antibodies, including compositions and methods of using such antibodies.
1. An anti-CCR8 antibody which comprises (i) a VH chain comprising three CDRs; and (ii) a VL chain comprising three CDRs, wherein:
VH CDR#1 is GFIFSNAVMY (SEQ ID NO:1);
VH CDR#2 is RIKTKFNNYATYYADAVKG (SEQ ID NO:2);
VH CDR#3 is GDRNKPFAY (SEQ ID NO:3);
VL CDR#1 is RASTSVITLLH (SEQ ID NO:4);
VL CDR#2 is GASNLES (SEQ ID NO:5); and
VL CDR#3 is QQSWNDPYT (SEQ ID NO:6).
2. The anti-CCR8 antibody of claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 8.
3. The anti-CCR8 antibody of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence set forth as SEQ ID NO: 9 and a light chain comprising the amino acid sequence set forth as SEQ ID NO: 10.
4. The anti-CCR8 antibody according to claim 3 , wherein the antibody is afucosylated.
5. A composition comprising a plurality of the anti-CCR8 antibodies of claim 1 .
6. The composition of claim 5 , wherein greater than 80% of the anti-CCR8 antibodies in the composition are afucosylated.